Shane Cloney-Clark

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 652 citations · Full text

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 78 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley et al. · The Lancet HIV · 2022 · 65 citations · Full text

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

Carolyn Rydyznski Moderbacher, Christina Kim, José Mateus et al. · Journal of Clinical Investigation · 2022 · 54 citations · Full text

Adaptive Immune System, Immunology, Immune Regulation +19